This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Okami Medical has raised $45 million to commercialize medical devices for stopping blood flow, the company said last week.  The company has developed technology that it claims could make vascular embolization faster and better. It competes with embolization coils such as Boston Scientific’s Interlock and Terumo’s Azur. Okami named Drew Hykes as CEO i ...